Bladder Cancer Therapeutics Market, which was USD 266.10 million in 2023, is expected to reach USD 409.93 million by 2030, at a CAGR of 5.4% during the forecast period 2023 to 2030.
Bladder cancer is defined as the uncontrolled growth of abnormal cells in the urinary bladder and typically affects older adults. The spread of cancerous cells into the bladder’s muscular wall is dangerous to one’s health, so early detection is essential. The most common treatments for bladder cancer are surgery, biological therapy, and chemotherapy, and the main cause of cancer occurrences can be tobacco use and exposure to certain toxic chemicals and gases. Bladder cancer is the fourth most common type of cancer in men, but it is less common in women. At present, a number of therapies have evolved to treat bladder cancers, which in turn build a high demand for the bladder cancer therapeutics market.
Bladder cancer, the ninth-most common cancer, was diagnosed in approximately 430,000 new cases worldwide in 2012, according to statistics released by the World Cancer Research Fund International. The bladder is responsible for holding urine before it exits the body during urination, and bladder cancer occurs when cancerous cells form in the bladder tissues.
To Get More Business Strategies Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/239
Note – Updated Version 2023 is available
🠺 Brief Introduction to the research report.
🠺 Table of Contents (Scope covered as a part of the study)
🠺 Top players in the market
🠺 Research framework (structure of the report)
🠺 Research methodology adopted by Coherent Market Insights
The three main types of bladder cancer are named after the type of cells that become malignant. These types are:–
- Transitional Cell Carcinoma: The most prevalent type of bladder cancer is transitional cell carcinoma, also known as urothelial carcinoma. This cancer originates in the urothelial cells lining the bladder.
- Squamous Cell Carcinoma: Squamous cell carcinoma is a type of bladder cancer that develops in the bladder due to prolonged irritation or infection and begins in the squamous cells.
- Adenocarcinoma: Bladder cancer that begins in the secretory cells (glandular) of the bladder lining is a rare type of bladder cancer.
A study conducted by the American Society of Clinical Oncology (ASCO) has revealed that urothelial carcinoma comprises approximately 90% of all bladder cancer cases, while squamous cell carcinoma and adenocarcinoma make up 4% and 2%, respectively. The remaining 4% of cases consist of rare types of bladder cancer such as sarcoma and small cell anaplastic cancer.
Doctors use different types of Bladder Cancer Therapeutics, which are primarily determined by the patient’s treatment preference, the type of bladder cancer, the potential side effects of the treatment, and the stage of the cancer.
Market classification for treatments for bladder cancer:
Types of Bladder Cancer in the World Market:
- Urothelial Carcinoma
- Squamous Cell Carcinoma
- Adenocarcinoma
worldwide market by type of treatment
- Surgery
- Transurethral bladder tumor resection (TURBT)
- Cystectomy
- Urinary Diversion
- Chemotherapy
- Intravesical (local) Chemotherapy
- Systemic (whole body) Chemotherapy
- Immunotherapy
- Intravesical Therapy
- Interferon Therapy
- Radiation Therapy
Market worldwide by test type
- Biopsy
- Cystoscopy
- Urine Cytology
- Urinalysis
- Bladder Ultrasound
Market Worldwide by Gender
- Men
- Women
Geographical Markets Worldwide
- North America
- Europe
- APAC
- Latin America
- Middle East
- Africa
Direct Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/239
Rising incidence rates, particularly in developed nations, are driving the market for bladder cancer treatments upward.
According to data released by the International Agency for Research on Cancer (IARC), developed countries account for 59% of bladder cancer cases, with Belgium having the highest number of reported cases of bladder cancer.
According to Cancer Research UK, a cancer research charity, around 10,100 new cases of bladder cancer were reported in the UK in 2014, accounting for approximately 3% of all new cancer cases. Additionally, a study by the American Society of Clinical Oncology (ASCO) has reported a recent 12% decrease in the incidence rate of the disease in the UK.
Bladder cancer is more common in men than women, as per a study by the Cancer Research Institute. In 2016, approximately 77,000 new cases of bladder cancer were diagnosed in the United States, leading to 16,000 deaths. Due to the continuous advancements in clinical research, the survival rate of people with bladder cancer has increased, with a rate of approximately 77% observed in the past few years. According to the American Cancer Society, bladder cancer accounts for 5% of all new cancer cases in the U.S.
Unhealthy habits are among the major reasons behind bladder cancer. Smoking is a primary cause, along with continuous exposure to industrial chemicals, drinking water with high levels of arsenic, a family history of bladder cancer, and long-term use of urinary catheters. In Africa and the Middle East, schistosomiasis and infested water are the leading causes of bladder cancer.
North America is currently the dominant region in the global bladder cancer therapeutics market, followed by Europe, due to the availability of advanced treatments, a developed economy, and easy access to advanced healthcare facilities. The Asia-Pacific (APAC) region is expected to witness a high growth rate in the near future, owing to factors such as increasing per capita income, developing economy, government initiatives to improve healthcare infrastructure, growing foreign direct investment (FDI) in healthcare, and a rapidly increasing aging population.
According to data released by the Department of Industrial Policy and Promotion (DIPP), the healthcare sector in India received FDI worth US$ 4.09 billion between April 2000 and September 2016. Additionally, medical tourism is a thriving business in the region, offering easy access to high-quality low-cost treatment options. The medical tourism industry in India alone generates approximately US$ 3 billion annually, creating a highly conducive environment for the growth of the bladder cancer therapeutics market in the region.
On the other hand, growth of the bladder cancer therapeutics market is restricted by factors such as high cost of treatment, minimal pipeline products, the asymptomatic nature of the disease, and the rising use of generic drugs. The American Cancer Society data indicates that the FDA has only approved one drug for bladder cancer in the last thirty years.
Sanofi S.A., F. Hoffmann-La Roche AG, Novartis, Pfizer, Eli Lilly and Co., GlaxoSmithKline, Bristol-Myers Squibb, Allergan Inc., AVI Biopharma Inc., and AstraZeneca plc are the prominent firms with a significant market presence in the bladder therapies market. Cisplatin, Nivolumab, Thiotepa, Atezolizumab, Doxorubicin Hydrochloride, Opdivo (Nivolumab), Platinol-AQ (Cisplatin), Platinol (Cisplatin), and Tecentriq are some of the main medications approved by the Food and Drug Administration for the treatment of bladder cancer (Atezolizumab).
| Report Attribute | Details |
|---|---|
| The market size value in 2023 | USD 266.10 million |
| The revenue forecast in 2030 | USD 409.93 million |
| Growth Rate | CAGR of 5.4% |
| The base year for estimation | 2022 |
| Historical data | 2017 – 2021 |
| Forecast period | 2023 – 2030 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | Types, End Users, Regions |
| Growth Drivers | Increasing prevalence of bladder cancer.
Advancements in diagnostic techniques. Growing aging population. |
| Restraints & Challenges | Limited treatment options
Lack of early detection methods Regulatory challenges |
Key Developments
- Market participants are implementing different business tactics like acquiring product approval from regulatory authorities to broaden their product range and fortify their market presence. For example, in May 2017, Merck & Co., a pharmaceutical enterprise, obtained approval from the U.S. Food and Drug Administration (FDA) for Keytruda (pembrolizumab), which is used to treat urothelial carcinoma, also known as bladder cancer.
- Major players in the market are implementing various growth strategies, including research and development, to expand their product portfolio. For example, in August 2019, Roche Holding AG, a Swiss healthcare company, reported positive results for its bladder cancer treatment, Tecentriq (atezolizumab), which met its co-primary endpoint in Phase III IMvigor 130 trial.
- Major players in the market are implementing various growth strategies, including research and development, to expand their product portfolio. For example, in August 2019, Roche Holding AG, a Swiss healthcare company, reported positive results for its bladder cancer treatment, Tecentriq (atezolizumab), which met its co-primary endpoint in Phase III IMvigor 130 trial.
We Offer Customized Report, Click Here @ https://www.coherentmarketinsights.com/insight/request-customization/239
Table of Content (TOC):
Chapter 1 Introduction and Overview
Chapter 2 Industry Cost Structure and Economic Impact
Chapter 3 Rising Trends and New Technologies with Major Key players
Chapter 4 Bladder Cancer Therapeutics Market Analysis, Trends, Growth Factor
Chapter 5 Bladder Cancer Therapeutics Market Application and Business with Potential Analysis
Chapter 6 Market Segment, Type, Application
Chapter 7 Bladder Cancer Therapeutics Market Analysis (by Application, Type, End User)
Chapter 8 Major Key Vendors Analysis of Bladder Cancer Therapeutics Market
Chapter 9 Development Trend of Analysis
Chapter 10 Conclusion
Explore More Reports
India immune oncology drugs market
Surface plasmon resonance market
Intramuscular vaccine adjuvants market
Hpapis and cytotoxic drugs manufacturing market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Email: sales@coherentmarketinsights.com
Phone: U.S.: +1-206-701-6702
U.K.: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837